Annual SGA
$7.48 M
-$3.86 M-34.05%
December 31, 2023
Summary
- As of February 21, 2025, MRKR annual SGA is $7.48 million, with the most recent change of -$3.86 million (-34.05%) on December 31, 2023.
- During the last 3 years, MRKR annual SGA has fallen by -$3.00 million (-28.61%).
- MRKR annual SGA is now -69.34% below its all-time high of $24.38 million, reached on December 31, 2018.
Performance
MRKR SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$854.70 K
-$287.20 K-25.15%
September 30, 2024
Summary
- As of February 21, 2025, MRKR quarterly SGA is $854.70 thousand, with the most recent change of -$287.20 thousand (-25.15%) on September 30, 2024.
- Over the past year, MRKR quarterly SGA has dropped by -$287.20 thousand (-25.15%).
- MRKR quarterly SGA is now -95.02% below its all-time high of $17.18 million, reached on December 31, 2018.
Performance
MRKR Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$1.76 B
-$9.70 M-0.55%
September 30, 2024
Summary
- As of February 21, 2025, MRKR TTM SGA is -$1.76 billion, with the most recent change of -$9.70 million (-0.55%) on September 30, 2024.
- Over the past year, MRKR TTM SGA has dropped by -$1.76 billion (-34257.63%).
- MRKR TTM SGA is now -96110.45% below its all-time high of -$1.83 million.
Performance
MRKR TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
MRKR Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -34.0% | -25.1% | -10000.0% |
| 3 y3 years | -28.6% | -25.1% | -10000.0% |
| 5 y5 years | -69.3% | -66.5% | -10000.0% |
MRKR Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -42.2% | at low | -77.1% | at low | -15.2% | at low |
| 5 y | 5-year | -42.2% | at low | -77.1% | at low | -37.6% | at low |
| alltime | all time | -69.3% | +1867.8% | -95.0% | +309.2% | <-9999.0% | at low |
Marker Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $854.70 K(-25.2%) | $4.59 M(-10.8%) |
| Jun 2024 | - | $1.14 M(-6.3%) | $5.15 M(-21.1%) |
| Mar 2024 | - | $1.22 M(-11.5%) | $6.53 M(-12.7%) |
| Dec 2023 | $7.48 M(-34.1%) | $1.38 M(-2.5%) | $7.48 M(-3.1%) |
| Sep 2023 | - | $1.41 M(-43.9%) | $7.71 M(-19.1%) |
| Jun 2023 | - | $2.52 M(+16.2%) | $9.54 M(-6.1%) |
| Mar 2023 | - | $2.17 M(+34.2%) | $10.15 M(-13.4%) |
| Dec 2022 | $11.34 M(-12.3%) | $1.62 M(-50.0%) | $11.72 M(-10.5%) |
| Sep 2022 | - | $3.23 M(+3.2%) | $13.09 M(-0.0%) |
| Jun 2022 | - | $3.14 M(-16.0%) | $13.10 M(-3.1%) |
| Mar 2022 | - | $3.73 M(+24.9%) | $13.52 M(+4.6%) |
| Dec 2021 | $12.92 M(+23.4%) | $2.99 M(-7.7%) | $12.92 M(+3.7%) |
| Sep 2021 | - | $3.24 M(-9.0%) | $12.46 M(+5.7%) |
| Jun 2021 | - | $3.56 M(+13.4%) | $11.79 M(+9.4%) |
| Mar 2021 | - | $3.14 M(+24.3%) | $10.78 M(+3.0%) |
| Dec 2020 | $10.47 M(+5.0%) | $2.52 M(-1.9%) | $10.47 M(+6.2%) |
| Sep 2020 | - | $2.57 M(+1.0%) | $9.86 M(+0.4%) |
| Jun 2020 | - | $2.55 M(-9.9%) | $9.82 M(-1.7%) |
| Mar 2020 | - | $2.83 M(+47.7%) | $10.00 M(+0.2%) |
| Dec 2019 | $9.98 M(-59.1%) | $1.91 M(-24.5%) | $9.98 M(-60.5%) |
| Sep 2019 | - | $2.54 M(-6.8%) | $25.24 M(-0.1%) |
| Jun 2019 | - | $2.72 M(-3.0%) | $25.26 M(-1.3%) |
| Mar 2019 | - | $2.81 M(-83.7%) | $25.59 M(+5.0%) |
| Dec 2018 | $24.38 M(+280.2%) | $17.18 M(+573.3%) | $24.38 M(+188.6%) |
| Sep 2018 | - | $2.55 M(-16.4%) | $8.45 M(+0.0%) |
| Jun 2018 | - | $3.05 M(+91.1%) | $8.44 M(+28.3%) |
| Mar 2018 | - | $1.60 M(+28.4%) | $6.58 M(+2.7%) |
| Dec 2017 | $6.41 M(+36.7%) | $1.24 M(-51.2%) | $6.41 M(+1.7%) |
| Sep 2017 | - | $2.55 M(+114.1%) | $6.30 M(+17.5%) |
| Jun 2017 | - | $1.19 M(-16.6%) | $5.37 M(+0.2%) |
| Mar 2017 | - | $1.43 M(+25.9%) | $5.35 M(+14.1%) |
| Dec 2016 | $4.69 M(+5.5%) | $1.13 M(-29.6%) | $4.69 M(-27.0%) |
| Sep 2016 | - | $1.61 M(+36.9%) | $6.43 M(+15.1%) |
| Jun 2016 | - | $1.18 M(+53.3%) | $5.58 M(+4.5%) |
| Mar 2016 | - | $768.00 K(-73.2%) | $5.34 M(+7.0%) |
| Dec 2015 | $4.45 M(+39.8%) | $2.87 M(+272.9%) | $4.99 M(+107.4%) |
| Sep 2015 | - | $769.20 K(-17.9%) | $2.41 M(-19.5%) |
| Jun 2015 | - | $936.90 K(+123.7%) | $2.99 M(+17.6%) |
| Mar 2015 | - | $418.80 K(+48.1%) | $2.54 M(-22.7%) |
| Dec 2014 | $3.18 M(+61.8%) | $282.70 K(-79.1%) | $3.29 M(-12.0%) |
| Sep 2014 | - | $1.35 M(+176.7%) | $3.73 M(+41.3%) |
| Jun 2014 | - | $488.40 K(-58.0%) | $2.64 M(+6.4%) |
| Mar 2014 | - | $1.16 M(+59.2%) | $2.48 M(+26.4%) |
| Dec 2013 | $1.97 M(-55.6%) | $731.00 K(+180.8%) | $1.97 M(+3.6%) |
| Sep 2013 | - | $260.30 K(-21.0%) | $1.90 M(-11.7%) |
| Jun 2013 | - | $329.50 K(-49.0%) | $2.15 M(-53.4%) |
| Mar 2013 | - | $645.80 K(-2.5%) | $4.61 M(+4.2%) |
| Dec 2012 | $4.43 M | $662.30 K(+29.6%) | $4.42 M(-0.7%) |
| Sep 2012 | - | $510.90 K(-81.7%) | $4.45 M(+0.2%) |
| Jun 2012 | - | $2.79 M(+507.5%) | $4.45 M(+102.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | $459.60 K(-33.6%) | $2.20 M(-9.6%) |
| Dec 2011 | $2.43 M(-38.3%) | $691.90 K(+37.5%) | $2.43 M(-5.5%) |
| Sep 2011 | - | $503.20 K(-7.8%) | $2.57 M(-6.5%) |
| Jun 2011 | - | $545.80 K(-21.1%) | $2.75 M(-14.3%) |
| Mar 2011 | - | $692.20 K(-16.9%) | $3.21 M(-18.5%) |
| Dec 2010 | $3.94 M(-3.8%) | $832.50 K(+22.1%) | $3.94 M(-35.7%) |
| Sep 2010 | - | $681.80 K(-32.2%) | $6.13 M(+4.8%) |
| Jun 2010 | - | $1.01 M(-29.2%) | $5.85 M(+11.2%) |
| Mar 2010 | - | $1.42 M(-52.9%) | $5.26 M(+28.3%) |
| Dec 2009 | $4.10 M(+212.6%) | $3.02 M(+648.5%) | $4.10 M(+81.3%) |
| Sep 2009 | - | $403.20 K(-3.0%) | $2.26 M(-21.1%) |
| Jun 2009 | - | $415.60 K(+59.7%) | $2.87 M(-0.6%) |
| Mar 2009 | - | $260.20 K(-78.0%) | $2.88 M(-4.6%) |
| Dec 2008 | $1.31 M(-37.0%) | $1.18 M(+17.0%) | $3.02 M(+20.8%) |
| Sep 2008 | - | $1.01 M(+133.4%) | $2.50 M(+29.7%) |
| Jun 2008 | - | $432.20 K(+8.4%) | $1.93 M(-15.5%) |
| Mar 2008 | - | $398.60 K(-39.7%) | $2.28 M(+9.7%) |
| Dec 2007 | $2.08 M(+193.5%) | $660.50 K(+51.5%) | $2.08 M(+27.9%) |
| Sep 2007 | - | $436.00 K(-44.5%) | $1.63 M(+9.2%) |
| Jun 2007 | - | $786.00 K(+298.6%) | $1.49 M(+82.9%) |
| Mar 2007 | - | $197.20 K(-4.9%) | $814.60 K(+14.9%) |
| Dec 2006 | $708.70 K(+19.4%) | $207.40 K(-30.7%) | $708.70 K(+22.6%) |
| Sep 2006 | - | $299.10 K(+169.7%) | $577.90 K(+33.3%) |
| Jun 2006 | - | $110.90 K(+21.5%) | $433.60 K(-19.9%) |
| Mar 2006 | - | $91.30 K(+19.2%) | $541.20 K(-8.8%) |
| Dec 2005 | $593.70 K(-60.8%) | $76.60 K(-50.5%) | $593.60 K(-44.5%) |
| Sep 2005 | - | $154.80 K(-29.2%) | $1.07 M(-10.0%) |
| Jun 2005 | - | $218.50 K(+52.1%) | $1.19 M(-4.9%) |
| Mar 2005 | - | $143.70 K(-74.0%) | $1.25 M(-17.5%) |
| Dec 2004 | $1.51 M(-62.3%) | $552.90 K(+101.6%) | $1.51 M(-46.5%) |
| Sep 2004 | - | $274.20 K(-1.8%) | $2.83 M(-9.6%) |
| Jun 2004 | - | $279.20 K(-31.6%) | $3.13 M(-18.2%) |
| Mar 2004 | - | $408.00 K(-78.2%) | $3.83 M(-4.8%) |
| Dec 2003 | $4.01 M(+184.3%) | $1.87 M(+226.2%) | $4.02 M(+30.9%) |
| Sep 2003 | - | $573.60 K(-41.2%) | $3.07 M(+10.7%) |
| Jun 2003 | - | $975.80 K(+62.7%) | $2.77 M(-0.6%) |
| Mar 2003 | - | $599.90 K(-34.9%) | $2.79 M(+20.8%) |
| Dec 2002 | $1.41 M(+271.3%) | $921.70 K(+232.9%) | $2.31 M(+61.7%) |
| Sep 2002 | - | $276.90 K(-72.1%) | $1.43 M(+18.2%) |
| Jun 2002 | - | $992.30 K(+726.9%) | $1.21 M(+430.8%) |
| Mar 2002 | - | $120.00 K(+203.0%) | $227.70 K(-40.0%) |
| Dec 2001 | $379.90 K(-21.1%) | $39.60 K(-30.2%) | $379.80 K(-656.1%) |
| Sep 2001 | - | $56.70 K(+397.4%) | -$68.30 K(-127.1%) |
| Jun 2001 | - | $11.40 K(-95.8%) | $252.30 K(-18.5%) |
| Mar 2001 | - | $272.10 K(-166.6%) | $309.40 K(+25.7%) |
| Dec 2000 | $481.50 K(-42.3%) | -$408.50 K(-208.3%) | $246.20 K(-62.4%) |
| Sep 2000 | - | $377.30 K(+450.8%) | $654.70 K(+136.0%) |
| Jun 2000 | - | $68.50 K(-67.2%) | $277.40 K(+32.8%) |
| Mar 2000 | - | $208.90 K | $208.90 K |
| Dec 1999 | $834.00 K | - | - |
FAQ
- What is Marker Therapeutics annual SGA?
- What is the all time high annual SGA for Marker Therapeutics?
- What is Marker Therapeutics annual SGA year-on-year change?
- What is Marker Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Marker Therapeutics?
- What is Marker Therapeutics quarterly SGA year-on-year change?
- What is Marker Therapeutics TTM SGA?
- What is the all time high TTM SGA for Marker Therapeutics?
- What is Marker Therapeutics TTM SGA year-on-year change?
What is Marker Therapeutics annual SGA?
The current annual SGA of MRKR is $7.48 M
What is the all time high annual SGA for Marker Therapeutics?
Marker Therapeutics all-time high annual SGA is $24.38 M
What is Marker Therapeutics annual SGA year-on-year change?
Over the past year, MRKR annual SGA has changed by -$3.86 M (-34.05%)
What is Marker Therapeutics quarterly SGA?
The current quarterly SGA of MRKR is $854.70 K
What is the all time high quarterly SGA for Marker Therapeutics?
Marker Therapeutics all-time high quarterly SGA is $17.18 M
What is Marker Therapeutics quarterly SGA year-on-year change?
Over the past year, MRKR quarterly SGA has changed by -$287.20 K (-25.15%)
What is Marker Therapeutics TTM SGA?
The current TTM SGA of MRKR is -$1.76 B
What is the all time high TTM SGA for Marker Therapeutics?
Marker Therapeutics all-time high TTM SGA is -$1.83 M
What is Marker Therapeutics TTM SGA year-on-year change?
Over the past year, MRKR TTM SGA has changed by -$1.76 B (-34257.63%)